Evolent

Predictive genomics is reshaping the future of cancer care. I recently spoke with Mary Caffrey on the AJMC Managed Care Cast about how this rapidly evolving science can identify inherited cancer risks, help guide clinical decision-making, and anticipate how individual patients will respond to therapy. This evolution is happening so quickly, in fact, that we’re faced with a new challenge. New genetic tests are coming to the market so quickly that it’s nearly impossible for clinicians to know which ones are high value and then integrate them into daily patient care. Bridging the gap between innovation and integration is essential, which is why Evolent is bringing its clinical expertise to help health plans and providers navigate this complex landscape.   Listen to the podcast: https://lnkd.in/gAYJrry6   #Health #Healthcare #Genomics #PrecisionMedicine #Oncology #Evolent #GeneticTesting

A decade ago, Evolent became a public company on the NYSE. Today, we were back in New York and rang the opening bell to celebrate a decade of dedication to changing the health of the nation. I’m proud of what we’ve built as a company to date, and I’m appreciative of the many who have helped along the way. In reflecting on the experience, I'm especially inspired by the next generation of leaders who joined us in New York for this milestone moment. This select group represents the first cohort of Evolent’s new talent development programs—an initiative designed to accelerate the growth of our top talent and shape the leaders who will define Evolent’s future. Through the program, emerging leaders will have the unique opportunity to network with our founding leaders and current board members, engage in strategic development discussions, and help usher in a new chapter for Evolent. Celebrating this milestone with them makes the moment even more significant.    To the entire Evolent team—past and present—cheers to another decade of helping those navigating through complex health journeys.

This morning Evolent had the honor of ringing the NYSE Opening Bell, commemorating 10 years as a publicly traded company. It was a moment to reflect and celebrate Evolent’s past, present, and future. In addition to the Evolent executive team and members of its Board of Directors, Evolent brought together members of the inaugural class of a newly launched program to develop the next generation of Evolent leaders.   Thank you to the New York Stock Exchange for hosting us and to all of our team members and special guests who made the event so meaningful. And to the entire Evolent team, thank you for everything you do each and every day to advance our mission and deepen our impact. Congratulations on the past decade and here’s to the next!

The NYSE welcomes Evolent to celebrate its 10th anniversary of listing! (NYSE: EVH)

Tune in tomorrow morning – Tuesday, July 29 – as Evolent rings the NYSE Opening Bell to commemorate the 10-year milestone of becoming a public company. You can watch live right here on LinkedIn at 9:30 a.m. ET via the NYSE live feed from the event. 

Immunotherapy has changed the paradigm for treating many types of cancer. Still, there’s wide variation in how much these treatments help patients -- if they help at all. I spoke with Tamara N. Thomas at Urban Health Today about the promise and limitations of PD-L1 inhibitors, and why better patient selection is crucial to ensure these powerful but costly therapies deliver true benefits. The good news is that we’re getting closer to more effective and personalized care, especially with advances in biomarker testing and emerging AI tools.   Read the article: https://lnkd.in/dDHAXU3j   #Health #Healthcare #Oncology #Immunotherapy  

We’re thrilled to announce two additions to our leadership team.    Physician, executive and startup entrepreneur David Lim, MD, PhD has joined Evolent as our new chief clinical officer. Among other leadership roles, David was a founding team member of virtual physical therapy company RightMove Health and behavioral health company Quartet Health.      In addition, John Way has joined Evolent as CFO, Performance Suite, where he will oversee our at-risk specialty condition management products. He brings more than 20 years of executive financial management experience to the role, including as CFO of OptumHealth and OptumCare.    Welcome, Dave and John!   Read the press release: https://lnkd.in/ecjnyCNm

In an increasing number of cancer treatment scenarios, genetic testing of patients’ tumors is pointing the way to the best treatment options. But did you know that in addition to answering “Which drug?” genomic profiling can sometimes offer insights into “How much?” For example, genetic variations in one enzyme affects how people metabolize tamoxifen, a common medication used in breast cancer. Learn more about the emerging field of pharmacogenomics and other trends in predictive genomics in this insightful article by Dr. Sadie Dobrozsi, which appeared in AJMC - The American Journal of Managed Care’s Evidence-Based Oncology.  https://lnkd.in/eZsjSqKE #oncology #genetictesting

What would you do with a month of paid time off? Would you take a bucket-list international vacation, go on lots of hikes, catch up on reading, or just rest and reflect? For Gazala Sayyed, the answer was “all of the above.” Read her post about her recent sabbatical, a benefit that lets Evolent employees take off a month after every five years of service. 

A virtual mosaic filled with moving stories of cancer journeys, like a child diagnosed with leukemia at 18 months who is now a cancer-free kindergarten graduate.  A clinician-led discussion for over 200 employees that shared decades of insights and guidance about cancer treatment, survivorship, and how a cancer diagnosis changes the way people think about living. A leadership-driven campaign encouraging employees to get recommended cancer screenings using company-provided time off -- without losing vacation days.   These are just a few of the ways that Evolent has honored National Cancer Survivor’s Month across June.  Evolent’s work in oncology seeks to improve survivorship through high-quality, connected care. But the professional turns personal because all of us have been touched by cancer in one way or another. Where others may see a health plan member or patient, we see a family member or friend facing a cancer journey. That personal connection fuels our commitment to ensuring our members get the best tests and treatments in a connected care experience.  One of the reasons I came to Evolent is our core belief that every person deserves the same quality of care we would want for our loved ones. As National Cancer Survivors Month draws to a close, I am proud to work for a company that channels the care we provide to our customers each day to drive the health and wellbeing of our teammates. #nationalcancersurvivormonth #oncology #cancer #evolentclinical #nationalcancersurvivorsmonth